Emergent BioSolutions to Release Fourth Quarter and Full Year 2011 Financial Results and Conduct a Conference Call on March 8, 2012

ROCKVILLE, Md.–(BUSINESS WIRE)–Jan. 30, 2012– Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will report financial results for the fourth quarter and full year 2011 on Thursday, March 8, 2012, after market close.
Company management will host a conference call at 5:00 pm Eastern on March 8, 2012 to discuss the financial results for the [...]

February 3, 2012  Tags: , , , ,   Posted in: Chief executive officer, El-Hibri, Investors, Revenue, fuad  No Comments

Fuad El-Hibri and the TAKREEM Achievement Awards

TAKREEM was created as a venue in which to recognize outstanding accomplishments of Arab men and women. Through the TAKREEM Achievement Awards excellence in the Arab world is identified and highlighted, communicating to the level of experience and expertise among organizations and individuals present among Arabs living throughout the world.
Awards are given in ten categories including [...]

November 7, 2011  Tags: , , , , ,   Posted in: Arab, Chief executive officer, Emergent BioSolutions, fuad el-hibri  No Comments

Fuad El-Hibri on Arabian Business Power 500

ArabianBusiness.com focuses on the business of Arabs around the globe. The site’s Power 500 list identifies the world’s most influential Arabs, chronicling their achievements; a veritable who’s who among the most successful Arabs in the world. Men and women on the list contribute to a variety of fields including banking and finance, construction, media, [...]

October 27, 2011  Tags: , , , , ,   Posted in: Arab, Chief executive officer, Emergent BioSolutions, fuad el-hibri  No Comments

Fuad El-Hibri Announces Emergent BioSolutionsAward to Supply BioThrax Anthrax Vaccine to U.S. Government

Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions Inc.,(NYSE: EBS) announced that, in response to solicitation RFP-2011-N-13414, it has received an award to supply the U.S. government with 44.75 million doses of BioThrax(R) (Anthrax Vaccine Adsorbed) over a period of five years for a total value of up to $1.25 billion. BioThrax is [...]

October 14, 2011  Tags: , , , ,   Posted in: BioDefense, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, US Food and Drug Administration., fuad el-hibri  No Comments

Fuad El-Hibri Interviewed by Ricardo Karam

Fuad El-Hibri was interviewed a few months ago by Ricardo Karam. This interview was aired in the 2011 season on the Ricardo Karam’sShow, which focuses on successful people from the Arab community. Ricardo Karam is a well known talk show host who has interviewed many high profile people, such as Celine Dion, Charles Aznavour, Paolo [...]

September 7, 2011  Tags: , , , , ,   Posted in: Chief executive officer, Emergent BioSolutions, fuad el-hibri  No Comments

Emergent Announces Initiation of a Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed – Indolent Lymphoma

ROCKVILLE, Md., Aug 17, 2011 –
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 1b/2 study (16011) of TRU-016 in combination with rituximab and bendamustine for patients with relapsed indolent non-Hodgkin’s B-cell lymphomas, including follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma. TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical(TM) protein therapeutic in development for [...]

August 24, 2011  Tags: , , ,   Posted in: Chief Medical Officer, Chief executive officer, Clinical Research, Clinical trial, Emergent BioSolutions, Health Care, fuad el-hibri  No Comments

Emergent BioSolutions to Present at Wedbush 2011 Life Sciences Conference

ROCKVILLE, Md., Aug 09, 2011 (BUSINESS WIRE) –
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Wedbush 2011 Life Sciences Conference in New York on Wednesday, August 17, 2011 at 10:00 AM Eastern. During the presentation, a member of the company’s senior management team will provide a corporate [...]

August 15, 2011  Tags: , , , , ,   Posted in: Chief executive officer, Emergent BioSolutions, Investors, fuad el-hibri  No Comments

Emergent BioSolutions Chairman and CEO Fuad El-Hibri Appointed to U.S. Chamber of Commerce Board of Directors

ROCKVILLE, Md., Jun 13, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that its Chairman and Chief Executive Officer, Fuad El-Hibri, has been appointed to serve on the Board of Directors of the U.S. Chamber of Commerce. The U.S. Chamber of Commerce is the world’s largest business federation representing the interests of more [...]

June 20, 2011  Tags: , , , ,   Posted in: Chief executive officer, Emergent BioSolutions, entrepreneur, fuad el-hibri  No Comments

Emergent BioSolutions’ Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation

ROCKVILLE, Md., Jun 09, 2011 — Emergent BioSolutions Inc. (NYSE:EBS) announced today that its investigational anthrax vaccine, NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The vaccine candidate, also known as AV7909, consists of BioThrax(R) (Anthrax Vaccine Adsorbed) in combination with [...]

June 10, 2011  Tags: , , , ,   Posted in: Chief executive officer, Emergent BioSolutions, NuThrax, US Food and Drug Administration., fuad el-hibri  No Comments

Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule

ROCKVILLE, Md., May 31, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that eight lots of BioThrax(R) (Anthrax Vaccine Adsorbed) have received regulatory release for delivery to the U.S. government under the company’s contract (200-2009-30162) originally written to supply 14.5 million doses of BioThrax to the Strategic National Stockpile. This marks the largest [...]

June 7, 2011  Tags: , , , , ,   Posted in: Biothrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, US Food and Drug Administration., fuad el-hibri  No Comments